Olsson Anders G
Department of Medicine and Care, University Hospital, Linköping, Sweden.
Clin Ther. 2006 Nov;28(11):1747-63. doi: 10.1016/j.clinthera.2006.11.004.
The dose range for rosuvastatin in Europe has recently been expanded to 5 to 40 mg and is now in line with the dose range currently available in the United States.
The goal of this article was to review the efficacy and safety data available for the rosuvastatin 5-mg dose and discuss these data in the context of the full 5- to 40-mg dose range.
Articles referring to clinical efficacy or safety data for the 5-mg dose of rosuvastatin were identified and reviewed after a search of the MEDLINE database (2000-August 2006; English language only) using the search term rosuvastatin. Proceedings from major cardiology congresses (2000-2006) were also searched for additional information.
Rosuvastatin 5 mg is significantly (P < 0.001) more effective at reducing low-density lipoprotein cholesterol (LDL-C) and total cholesterol (42% and 30%) levels compared with atorvastatin 10 mg (36% and 27%), simvastatin 20 mg (36% and 25%), and pravastatin 20 mg (27% and 19%). Rosuvastatin 5 mg allows significantly more patients to reach their LDL-C goals as recommended by the 2003 European guidelines and the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (49%-52% and 67%-71%) than atorvastatin 10 mg (36%, P < 0.001; 53%, P < 0.01), simvastatin 20 mg (37%, P < 0.001; 64%, P < 0.05), and pravastatin 20 mg (12%, P < 0.001; 49%, P < 0.001). Rosuvastatin is well tolerated across the 5- to 40-mg dose range, with a type and incidence of adverse events similar to the other commonly available, but less effective, statins. The introduction of a 5-mg dose offers greater flexibility to prescribing physicians in that it provides an additional dosing option for those patients who are at a lower cardiovascular risk or who have an increased potential for developing myopathy with statin therapy.
Rosuvastatin 5 mg is well tolerated and has beneficial effects across the atherogenic lipid profile by reducing LDL-C and total cholesterol, raising high-density lipoprotein cholesterol, and helping a greater proportion of patients reach their LDL-C goals.
欧洲瑞舒伐他汀的剂量范围最近已扩大至5至40毫克，目前与美国现有的剂量范围一致。
本文的目的是回顾5毫克剂量瑞舒伐他汀的有效性和安全性数据，并在5至40毫克的完整剂量范围内讨论这些数据。
在使用搜索词“瑞舒伐他汀”搜索MEDLINE数据库（2000年至2006年8月；仅英文）后，识别并回顾了提及5毫克剂量瑞舒伐他汀临床疗效或安全性数据的文章。还搜索了主要心脏病学大会（2000年至2006年）的会议记录以获取更多信息。
与10毫克阿托伐他汀（分别降低36%和27%）、20毫克辛伐他汀（分别降低36%和25%）以及20毫克普伐他汀（分别降低27%和19%）相比，5毫克瑞舒伐他汀在降低低密度脂蛋白胆固醇（LDL-C）和总胆固醇水平方面显著更有效（P < 0.001）（分别降低42%和30%）。按照2003年欧洲指南以及美国国家胆固醇教育计划成人高胆固醇检测、评估和治疗专家小组第三次报告（成人治疗小组III）的建议，5毫克瑞舒伐他汀能使显著更多患者达到LDL-C目标（分别为49% - 52%和67% - 71%），高于10毫克阿托伐他汀（分别为36%，P < 0.001；53%，P < 0.01）、20毫克辛伐他汀（分别为37%，P < 0.001；64%，P < 0.05）以及20毫克普伐他汀（分别为12%，P < 0.001；49%，P < 0.001）。在5至40毫克的剂量范围内，瑞舒伐他汀耐受性良好，不良事件的类型和发生率与其他常用但效果较差的他汀类药物相似。5毫克剂量的引入为开处方的医生提供了更大的灵活性，因为它为那些心血管风险较低或他汀类药物治疗发生肌病可能性增加的患者提供了额外的给药选择。
5毫克瑞舒伐他汀耐受性良好，通过降低LDL-C和总胆固醇、升高高密度脂蛋白胆固醇以及帮助更大比例的患者达到LDL-C目标，对致动脉粥样硬化的血脂谱具有有益作用。
